Sign in

CIK 0001069530

  • Non-accelerated filer
  • Smaller reporting company

FILANA THERAPEUTICS, INC.

Sign in to watch
Ticker
FLNA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
911911336
Phone
+1 512-501-2444
Business address
6801 N CAPITAL OF TEXAS HIGHWAY, BUILDING 1; SUITE 300, AUSTIN, TX, 78731
Former names
CASSAVA SCIENCES INC, PAIN THERAPEUTICS INC
  1. 4 Shares withheld for taxes Chief Medical Officer gave up 23,996 shares (to pay taxes)
  2. 4 Shares withheld for taxes Director gave up 4,387 shares (to pay taxes)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Open-market buy President and CEO bought 10,000 shares at $9.59 ($95,900)
  8. 4 Open-market buy Director bought 36,281 shares at $8.92 ($323,627)
  9. 4 Open-market buy Chief Financial Officer bought 12,000 shares at an average $7.03 ($84,380)
  10. 4 Open-market buy Director bought 213,719 shares at $6.98 ($1,491,759)
  11. 4 Open-market buy President and CEO bought 100,000 shares at $5.53 ($553,000)
  12. 4 Open-market buy President and CEO bought 10,000 shares at $4.15 ($41,500)
  13. 4/A Open-market buy President and CEO bought 2,599 shares at $1.65 ($4,288)
  14. 4 Open-market buy President and CEO bought 2,599 shares at $1.65 ($4,288)
  15. 4 Open-market buy Director bought 423,788 shares at $2.20 ($932,334)
  16. 4 Open-market buy Chief Financial Officer bought 5,300 shares at $1.88 ($9,964)
  17. 4 Open-market buy Director bought 76,212 shares at $1.86 ($141,754)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 6 of 30 · 591 filings